Page-1
Trial Pending Trial Pending Trial Pending Cohorts 2 & 3: PDLI. Positive Disease progression on prior... HER2 + with either progression or intolerability of 1st line tx... Exon-19 deletion or L858R mutation after prog and at least 6... Group B: VICC THO 1042 A Phase 1-2 Trial of MM-121 in... VICC THN 1281 An Open-Label Randomized Phase III Trial of... VICC THN 1281 An Open-Label Randomized Phase III Trial of... VICC THN 1281 An Open-Label Randomized Phase III Trial of... VICC THN 1242 A Phase IB, Multi-Center,Open-Label Study of the... VICC THN 1242 A Phase IB, Multi-Center,Open-Label Study of the... VICC THN 1244 Phase 1, First-in-Human, Dose-Escalation Study to... VICC MD 1188 An Open-Label, Phase II Study of Vemurafenib in... VICC THN 1122 Open label two-stage study of orally administered... VICC THN 1123 A Phase II Study of the Selective BRAF Kinase... VICC THO 0730 A Phase II Trial of Celecoxib plus Chemotherapy... No prior EGFR TKI therapy in metastatic setting. Group C: VICC THO 1042 A Phase 1-2 Trial of MM-121 in... Prior treatment with EGFR inhibitor for known EGFR mutation or... VICC THO 0730 A Phase II Trial of Celecoxib plus Chemotherapy... VICC THO 0730 A Phase II Trial of Celecoxib plus Chemotherapy... Click here to print
this page (PDF) Lung Cancer Flowcharts: NSCLC Mets 2nd Line and Above